

Press release

Please fill in this form and return it to graduateschoolhealth@au.dk in Word format no later than three weeks prior to your defence.

Basic information

Name: Pernille Glahn Wernlund

Email: pernillewernlund@clin.au.dk Phone: 22406864

Department of: Clinical Medicine

Main supervisor: Jørgen Agnholt

Title of dissertation: Clinical and immune modulating effects of casein glycomacropeptide on healthy adults and patients with ulcerative colitis

Date for defence: 15/5 2020 at (time of day): 14.30 Place: Auditorium J116-113

Press release (Danish)

Effekten af valleproteinet casein glycomacropeptid på tarmen hos raske og patienter med kronisk tyktarmsbetændelse

Kronisk tyktarmsbetændelse (colitis ulcerosa) er en sygdom, der ofte rammer personer i alderen 20-40 år. Symptomerne omfatter mavesmerter, hyppige blodige diarreér, vægttab og træthed og kan være svært invaliderende for patienterne og føre til nedsat livskvalitet og tabt arbejdsevne. Sygdommen behandles med immundæmpende medicin, der kan forårsage svære bivirkninger og komplikationer foruden at være dyr. Både patienter og sundhedsprofessionelle efterlyser derfor andre behandlingsmuligheder. Casein glycomacropeptid har i celle- og dyremodeller vist sig at kunne dæmpe tarmbetændelse.

Et nyt ph.d.-projekt fra Aarhus Universitet, Health, har undersøgt den betændelsesdæmpende virkning af dette specifikke valleprotein i patienter med aktiv kronisk tyktarmsbetændelse og har belyst virkningsmekanismerne i raske frivillige forsøgspersoner. Projektet er gennemført på Lever-Mave-Tarm på Aarhus Universitets hospital af Pernille Glahn Wernlund, der forsvare det d.15/5.

Forsvaret af ph.d.-projektet er offentligt og finder sted den 15/5 kl. 14.30 i Auditorium J116-113, Aarhus Universitetshospital, Indgang J, plan1, Palle Juul-Jensens Boulevard, 8200 Aarhus N. Titlen på projektet er "Clinical and immune modulating effects of casein glycomacropeptide on healthy adults and patients with ulcerative colitis". Yderligere oplysninger: Ph.d.-studerende Pernille Glahn Wernlund, e-mail: pernillewernlund@clin.au.dk, tlf. 22406864.

Grundet Coronavirus situationen kan forsvaret overværes virtuelt. Send en e-mail til pernillewernlund@clin.au.dk hvis link til forsvaret ønskes.

Bedømmelsesudvalg:

Professor Ailsa Louise Hart, MD
Department of Surgery and Cancer, St Mark's Hospital
Imperial College London
London, UK

Professor Jens Kjeldsen, MD
Gastroenterologisk Afdeling, Odense Universitetshospital
Odense, Danmark

Professor Lars Iversen (Chairman), MD
Hud- og Kønssygdomme, Aarhus Universitetshospital
Institut for Klinisk Medicin, Aarhus Universitet

Aarhus, Danmark

Press release (English)

The effect of the whey protein casein glycomacropeptide on the colon in healthy adults and patients with inflammatory bowel disease.

Ulcerative colitis is often diagnosed at 20 to 40 years of age but affects children and elderly as well. The symptoms are abdominal pain, urgent bloody diarrhea, weight loss and fatigue. The disease affects the every day life of the patients and can be devastating to their quality of life. The therapy includes immunosuppressants and may have severe side effects and complication risks besides being costly. Both patients and care takers request alternative treatment strategies. The milk-derived protein casein glycomacropeptide has shown anti-inflammatory potential in cell and animal studies and may be able to reduce intestinal inflammation in patients with intestinal inflammation.

A ph.d. project from Aarhus University has investigated the effects of glycomacropeptid on patients with active ulcerative colitis og has assessed the way of action in healthy volunteers. The project was caried out on the Department of Hepatology and Gastroenterology, Aarhus University Hospital by Pernille Glahn Wernlund, who is defending her dissertation on May 15.

The defence is public and takes place on May 15, 2020, at 14.30 in Auditorium J116-113, Aarhus University Hospital, Entrance J, floor 1, Palle Juul-Jensens Boulevard, 8200 Aarhus N. The title of the project is "Clinical and immune modulating effects of casein glycomacropeptide on healthy adults and patients with ulcerative colitis". For further information, please contact: Ph.d. student Pernille Glahn Wernlund, e-mail: pernillewernlund@clin.au.dk, phone: +45 22406864.

Due to the Coronavirus situation, the defence can be streamed online. Send an e-mail to pernillewernlund@clin.au.dk if the link is needed.

Assessment committee:

Ailsa Louise Hart
Professor, MD
Department of Surgery and Cancer, St Mark´s Hospital
Imperial College London
London, UK

Jens Kjeldsen
Professor, MD
Department of Gastroenterology, Odense University Hospital
Odense, Denmark

Lars Iversen (Formand)
Professor, MD
Department of Dermatology and Venerology, Aarhus University Hospital
Department of Clinical Medicine, Aarhus University
Aarhus, Denmark

Permission

By sending in this form:

- I hereby grant permission to publish the above Danish and English press releases.
- I confirm that I have been informed that any applicable inventions shall be treated confidentially and shall under no circumstances whatsoever be published, presented or mentioned prior to submission of a patent application, and that I have an obligation to inform my head of department and the university's Patents Committee if I believe I have made an invention in connection with my work. I also confirm that I am not aware that publication violates any other possible holders of a copyright.

